reference replicate design [Design Issues]

posted by VG – India, 2014-01-13 13:18 (4546 d 09:54 ago) – Posting: # 12160
Views: 1,893

Dear all

Please let me know if reference replicate design (partial and fully replicate) is acceptable to the KFDA (Korea) for highly variable drugs. If so which methodology is to be followed (USFDA or EMA).


Regards

VG

Complete thread:

UA Flag
Activity
 Admin contact
23,655 posts in 4,993 threads, 1,571 registered users;
179 visitors (0 registered, 179 guests [including 42 identified bots]).
Forum time: 00:12 CEST (Europe/Vienna)

The great tragedy of Science – the slaying
of a beautiful hypothesis by an ugly fact.    Thomas Henry Huxley

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5